Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision
Language English Country United States Media print-electronic
Document type Journal Article, Practice Guideline
Grant support
G1000758
Medical Research Council - United Kingdom
PubMed
28602936
DOI
10.1016/j.jaci.2017.03.050
PII: S0091-6749(17)30919-3
Knihovny.cz E-resources
- Keywords
- Allergic rhinitis, practice guideline,
- MeSH
- Rhinitis, Allergic drug therapy epidemiology MeSH
- Histamine H1 Antagonists therapeutic use MeSH
- Anti-Allergic Agents therapeutic use MeSH
- Asthma prevention & control MeSH
- Child MeSH
- Clinical Decision-Making MeSH
- Quality of Life MeSH
- Evidence-Based Practice MeSH
- Humans MeSH
- Animals MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Practice Guideline MeSH
- Names of Substances
- Histamine H1 Antagonists MeSH
- Anti-Allergic Agents MeSH
BACKGROUND: Allergic rhinitis (AR) affects 10% to 40% of the population. It reduces quality of life and school and work performance and is a frequent reason for office visits in general practice. Medical costs are large, but avoidable costs associated with lost work productivity are even larger than those incurred by asthma. New evidence has accumulated since the last revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines in 2010, prompting its update. OBJECTIVE: We sought to provide a targeted update of the ARIA guidelines. METHODS: The ARIA guideline panel identified new clinical questions and selected questions requiring an update. We performed systematic reviews of health effects and the evidence about patients' values and preferences and resource requirements (up to June 2016). We followed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) evidence-to-decision frameworks to develop recommendations. RESULTS: The 2016 revision of the ARIA guidelines provides both updated and new recommendations about the pharmacologic treatment of AR. Specifically, it addresses the relative merits of using oral H1-antihistamines, intranasal H1-antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists either alone or in combination. The ARIA guideline panel provides specific recommendations for the choice of treatment and the rationale for the choice and discusses specific considerations that clinicians and patients might want to review to choose the management most appropriate for an individual patient. CONCLUSIONS: Appropriate treatment of AR might improve patients' quality of life and school and work productivity. ARIA recommendations support patients, their caregivers, and health care providers in choosing the optimal treatment.
Alfred Hospital and Monash University Melbourne Australia
Allergy and Respiratory Diseases IRCCS San Martino IST University of Genoa Genoa Italy
Asthma and Allergy Clinic Humanitas University Rozzano Milan Italy
Center of Rhinology and Allergology Wiesbaden Germany
Department of Allergy and Rheumatology Ajou University School of Medicine Suwon Korea
Department of Clinical Epidemiology and Biostatistics McMaster University Hamilton Ontario Canada
Department of Dermatology and Allergy Charité Universitätsmedizin Berlin Berlin Germany
Department of Medicine Royal College of Surgeons in Ireland Medical School Dublin Ireland
Department of Otorhinolaryngology Academic Medical Centre Amsterdam The Netherlands
Department of Paediatrics Oslo University Hospital University of Oslo Oslo Norway
Department of Pediatrics Division of Allergy and Immunology University of California San Diego Calif
Department of Pediatrics Nippon Medical School Tokyo Japan
Department of Public Health and Primary Care Leiden University Medical Center Leiden The Netherlands
Division of Allergy and Immunology University of South Florida Tampa Fla
Faculty of Medicine Transylvania University Brasov Romania
Hospital Médica Sur Mexico City Mexico
Institute of Family Medicine and Public Health University of Tartu Tartu Estonia
National Hospital Organization Tokyo National Hospital Kiyose city Tokyo Japan
Nova Southeastern University Fort Lauderdale Fla
ProAR Center of Excellence for Asthma Federal University of Bahia Salvador Brazil
University Clinic of Pulmonary and Allergic Diseases Golnik Golnik Slovenia
University Hospital Montpellier France
University of Aberdeen Aberdeen United Kingdom
Upper Airways Research Laboratory Ghent University Hospital Ghent Belgium
References provided by Crossref.org
Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK-air Study
A EUFOREA comment on a lost comorbidity of asthma
Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model
Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases
